IMGN ImmunoGen Inc.

+0.17  (+3%)
Previous Close 5.56
Open 5.6
Price To Book 18.48
Market Cap 854290112
Shares 149,090,770
Volume 1,727,423
Short Ratio
Av. Daily Volume 2,717,801

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 22 2013 - under priority review
2nd-line HER2+ Metastatic Breast Cancer
Phase 1b/2 triplet and mature doublet expansion cohort data due 2019.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 3 top-line data due 1H 2019.
Mirvetuximab soravtansine - FORWARD I
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 trial did not meet endpoints.
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Endpoint not met - October 2015
Kadcyla GATSBY trial
Cancer - metastatic HER2+ gastric cancer
Phase 3 data due in 2019.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy
Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial
Cancer - 1st-line HER2+ Metastatic Breast Cancer
Phase 1 updated data due 2019.
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Phase 1 additional data due at ASH December 1, 2018 noted 26% ORR; 7% CR.
Relapsed/refractory acute myeloid leukemia (AML)

Latest News

  1. Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries — New Research Emphasizes Economic Growth
  2. Healthcare Companies Investors are Watching
  3. How ImmunoGen, Inc. (NASDAQ:IMGN) Could Add Value To Your Portfolio
  4. Edited Transcript of IMGN earnings conference call or presentation 8-Feb-19 1:00pm GMT
  5. ImmunoGen Still Waiting to Take Its Leap "Forward"
  6. ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up
  7. Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock
  8. ImmunoGen (IMGN) Q4 2018 Earnings Conference Call Transcript
  9. ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
  10. ImmunoGen: 4Q Earnings Snapshot
  11. ImmunoGen Reports Recent Progress and 2018 Operating Results
  12. Why ImmunoGen Jumped Almost 14% Today
  13. Earnings Preview: ImmunoGen (IMGN) Q4 Earnings Expected to Decline
  14. ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results
  15. Have Insiders Been Selling ImmunoGen, Inc. (NASDAQ:IMGN) Shares This Year?
  16. The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study
  17. ImmunoGen Announces Sale of Residual Kadcyla Royalties
  18. Why ImmunoGen Jumped Today
  19. ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference
  20. Why ImmunoGen Shot Up 13% Today